immatics biotechnologies GmbH (4A3) — Capital Reinvestment Ratio
immatics biotechnologies GmbH (4A3) has a Capital Reinvestment Ratio of 0.12x as of December 2023, meaning it reinvests 0% of its operating cash flow (€79.08 Million) in capital expenditures (€9.29 Million). See 4A3 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
immatics biotechnologies GmbH Capital Reinvestment Ratio (2018–2023)
This chart tracks immatics biotechnologies GmbH's Capital Reinvestment Ratio across 6 annual periods. Check cash flow reinvestment rate of immatics biotechnologies GmbH to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for immatics biotechnologies GmbH (2018–2023)
Year-by-year Capital Reinvestment Ratio for immatics biotechnologies GmbH from 2018 to 2023. For live market cap and broader valuation context, see market cap of immatics biotechnologies GmbH.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.70x | €18.23 Million | €30.96 Million | ▲ +2863.7% |
| 2022 | 0.06x | €100.13 Million | €5.74 Million | ▲ +12.4% |
| 2021 | 0.05x | €100.13 Million | €5.11 Million | ▼ -31.2% |
| 2020 | 0.07x | €100.13 Million | €7.42 Million | ▲ +145.4% |
| 2019 | 0.03x | €70.97 Million | €2.14 Million | ▲ +45.6% |
| 2018 | 0.02x | €20.68 Million | €429.00K | — |